Pathway
JAK-STAT signalling
Core intracellular signalling route used by many cytokine receptors.
Also called: JAK-STAT, Janus kinase-STAT, JAK/STAT
In short
- 1What it is: a pathway in signalling and mechanisms.
- 2How it connects: acts on 1 and is affected by 4 concepts — mostly 2 molecule, 2 receptor, 1 disease.
- 3Where it sits: signalling, target on the 15-step immune chain.
What it does
Downstream of most cytokine receptors (IL-6R→JAK1/TYK2→STAT3; IL-4R→JAK1/JAK3→STAT6; IFN-αβR→JAK1/TYK2→STAT1/2; IL-2R→JAK1/JAK3→STAT5); JAK1/2/3 inhibitors (baricitinib/tofacitinib/upadacitinib) approved across RA, AD, IBD, alopecia, COVID-19; FDA 2021 boxed warning for JAK inhibitors (MACE/VTE/malignancy) in patients ≥50y with ≥1 CV risk factor; deucravacitinib (allosteric TYK2 JH2 domain) selectively blocks IL-12/IL-23/IFN-I, no JAK class boxed warning
Its connections at a glance
Each dot is a concept directly linked to JAK-STAT signalling. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID P002 · concept status: established. Select any connection above to inspect evidence for that specific link.